The U.S. Food and Drug Administration (FDA) has cleared two new AI apps for Exo’s handheld ultrasound device, Exo Iris.
Clearances for AI that can detect pleural effusion and consolidation/atelectasis bring the number of FDA-cleared algorithms embedded in the device to 14, the company said. The new apps can provide clinicians with objective data to help detect lung diseases like pneumonia and tuberculosis at the bedside in seconds, Exo said.
Exo introduced Exo Iris in September 2023.
